Acadia Upgraded To Buy From Neutral At Goldman Sachs
March 31, 2020 at 06:54 AM EDT
Goldman Sachs analyst Salveen Richter upgraded Acadia Pharmaceuticals to Buy from Neutral with a price target of $72, up from $45.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|